BiTE secretion from in situ-programmed myeloid cells results in tumor-retained pharmacology

Bispecific T-Cell Engagers (BiTEs) are effective at inducing remission in hematologic cancers, but their use in solid tumors has been challenging due to their extreme potency and on-target, off-tumor toxicities in healthy tissue. Their deployment against solid tumors is further complicated by insuff...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Journal of controlled release 2022-02, Vol.342, p.14-25
Hauptverfasser:	Hao, S., Inamdar, V.V., Sigmund, E.C., Zhang, F., Stephan, S.B., Watson, C., Weaver, S.J., Nielsen, U.B., Stephan, M.T.
Format:	Artikel
Sprache:	eng
Schlagworte:	Bi-specific T-cell engagers (BiTEs) In situ gene therapy Nanotechnology
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!